04Ene 2014
wiley-logo

The trabecular bone score (TBS) is a gray‐level textural metric that can be extracted from the two‐dimensional lumbar spine dual‐energy X‐ray absorptiometry (DXA) image.

TBS is related to bone microarchitecture and provides skeletal information that is not captured from the standard bone mineral density (BMD) measurement.

Based on these data, lumbar spine TBS holds promise as an emerging technology that could well become a valuable clinical tool in the diagnosis of osteoporosis and in fracture risk assessment.

Autor: Barbara C Silva, William D Leslie, Heinrich Resch,…
04Ene 2014
wiley-logo

In conclusion, despite the huge impact of osteoporosis worldwide, our knowledge of bone genetics and biology remains remarkably incomplete.

Our findings and models provide compelling genetic evidence of a novel molecular network regulating adult skeletal homeostasis in vivo, which may help identify new specific therapeutic targets against involution- al, inflammatory, or cancer‐induced bone wasting.

Autor: Elisa Benasciutti, Elisabetta Mariani, Laura Oliva, Maria Scolari,…
04Dic 2013
Springer

Calcified Tissue International (2014) 94:4: 423-432

They conclude that Cnr2 deficiency affects expression of a large number of genes in different strains of mice, and that these differences are likely to be responsible in part for the differences in skeletal phenotype that they and others have observed in mice with defective cannabinoid receptor signalling in different genetic backgrounds.

Autor: Sophocleous A, Sims AH, Idris AI, Ralston SH
04Dic 2013
Springer

Osteoporos Int (2014) 25:1267–1274. DOI 10.1007/s00198-013-2586-0.

Conclusions This study supports other international studies by showing changes in the incidence of hip fractures after age population adjustment, which denotes a decrease in the younger age groups and among women and shows an increase in both groups over 85 years. The increase in the crude incidence rate of hip fracture in Spain reflects changes in population structure.

Autor: Azagra R, L-Expósito F, Martin-S JC, Aguyé A, Moreno N, Cooper C, D-Pérez A, Dennison EM
04Dic 2013
Springer

The results of this nested case–control study in the CPRD indicate no evidence for a higher risk of MI or cardiovascular death associated with the use of strontium ranelate

in women treated for osteoporosis compared with non-use of this agent in routine medical practice in the UK.

Autor: C. Cooper, K. M. Fox, J. S. Borer
04Dic 2013
wiley-logo

In conclusion, our data highlight the potential for novel drug targeting approaches in rare skeletal disorders ranging from severe skeletal fragility to sclerosing bone overgrowth through selective modulation of canonical WNT signaling.

These approaches should also be beneficial in the context of other medical conditions with much less severe phenotypes, such as postmenopausal osteoporosis, given the crucial role of this potent bone anabolic pathway for skeletal homeostasis

Autor: Ming‐Kang Chang, Ina Kramer, Hansjoerg Keller,…
04Nov 2013
Springer

Osteoporos Int (2014) 25:1225–1235

This is the first network meta-analysis to assess the comparative GI safety of bisphosphonates for primary osteoporosis. Our results identify zoledronic acid as having the highest probability of having the greatest number of GI adverse events and nausea. Discontinuation due to adverse events may be a more clinically relevant outcome, with the highest probability of greatest occurrence found with etidronate and zoledronic acid. These results question the assumption that annual zoledronic acid will translate into better adherence. Little difference was found between alendronate and risedronate for serious AE. More research into real-world implications of the comparative safety of bisphosphonates is needed.

Autor: M. Tadrous, L. Wong,M. M. Mamdani,D. N. Juurlink ,M. D. Krahn,L. E. Lévesque ,S. M. Cadarette
04Sep 2013
wiley-logo

J Bone Miner Res, (2014) 29; 787–795

The findings represent the first demonstration, using a direct in vivo measure of BMS, of compromised bone material properties in patients with T2D. Further, our results confirm previous studies demonstrating low bone turnover in patients with T2D and highlight the potential detrimental effects of prolonged hyperglycemia on bone quality. Thus, the skeleton needs to be recognized as another important target tissue subject to diabetic complications.

Autor: J N Farr,1 M T Drake,1 S Amin,2 L J Melton III,3 L K McCready,1 Sundeep Khosla1
04Ago 2013
Springer

In conclusion, baseline cardiovascular diseases are common in patients treated with strontium ranelate, with more than half of strontium ranelate users being current

users of antiplatelet drugs or having a history of cerebrovascular disease, peripheral vascular disease or myocardial infarction. Moreover, this observational study shows an increased confounder-adjusted mortality risk in patients treated with strontium ranelate compared with other osteoporosis drugs.

Autor: B. Abrahamsen, E. L. Grove, P. Vestergaard
04Jun 2013
europepmc_logo

Froedtert Healthcare, Patient Care Services, Milwaukee, WI, USA, ryanpa@uwm.edu.

Ryan P, Schlidt A, Ryan C
Froedtert Healthcare, Patient Care Services, Milwaukee, WI, USA, ryanpa@uwm.edu.
Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [2013]

Autor: Journal Established as Result of Cooperation Between…